Form 4: Intra-Cellular Therapies EVP and General Counsel Halstead Michael Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies, reports the acquisition of 36,717 restricted stock units on March 1, 2024.
Summary
- On March 1, 2024, Michael Halstead, the EVP and General Counsel of Intra-Cellular Therapies, acquired 36,717 restricted stock units.
- These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
- Each restricted stock unit represents the contingent right to receive one share of common stock.
Sentiment
Score: 5
Explanation: This Form 4 filing is a routine disclosure of stock options granted to an executive, and does not contain any information that would significantly impact investor sentiment.
Future Outlook
The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date.
Industry Context
This is a standard disclosure related to executive compensation, reflecting alignment of management interests with shareholder value through equity-based awards.
Stakeholder Impact
- The granting of restricted stock units aligns the executive's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: Michael Halstead was granted 36,717 restricted stock units. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.